A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma (NCT05370144)
Phase II Study of Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
🩺 Plain-English Summary (8th-Grade Level)
An open-label, single-centre, non-randomized, Phase II trial in patients with esophageal adenocarcinoma. This study aims to show that delivering hypofractionated neoadjuvant concurrent chemoradiotherapy is is equally effective as conventionally fractionated neoadjuvant concurrent chemoradiotherapy.
Who can join: Review the eligibility criteria below.
Location: Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
- Hypofractionated radiotherapy (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
📞 Contact the Study Coordinator
Phone: (587) 231-6117
Email: Sangjune.Lee@albertahealthservices.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Esophageal Cancer
- Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer — Philadelphia, Pennsylvania
- Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial — Houston, Texas
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors — Los Angeles, California
- Genetic and Environmental Risk Factors Related to Esophageal Cancer — Boston, Massachusetts
- Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer — Winnipeg, Manitoba
- Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract — New York, New York
Explore by condition: All Esophageal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.